[Bispecific antibodies in multiple myeloma].

Myélome multiple et anticorps bispécifiques.
ADP-ribosyl Cyclase 1 / immunology Antibodies, Bispecific / immunology Antigens, Neoplasm / immunology Drug Resistance, Neoplasm / immunology Humans Immunotherapy / methods Multiple Myeloma / immunology Receptors, Fc / immunology Receptors, G-Protein-Coupled / immunology Signaling Lymphocytic Activation Molecule Family / immunology T-Lymphocytes / immunology
Anticorps bispécifiques BCMA Bispecific antibodies in multiple myeloma Immunothérapie

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 12 07 2021
revised: 17 10 2021
accepted: 18 10 2021
entrez: 18 12 2021
pubmed: 19 12 2021
medline: 30 12 2021
Statut: ppublish

Résumé

Immunotherapies have recently emerged as potential game changers in the treatment of multiple myeloma (MM). Those include monoclonal antibodies (targeting CD38 or CS1), bispecific antibodies (BsAb, mainly targeting BCMA, GPRC5D or FcRH5), antibody-drug conjugate (mainly targeting BCMA) and CAR-T cells (mainly targeting BCMA). BsAb have the capacity to bind two different antigens, one at the tumor cell surface and one on T cells (CD3), recreating the immune synapse. In this article, we discuss the main clinical data on BsAb in MM, as well as their different constructs and the potential mechanism of resistance.

Identifiants

DOI: 10.1016/j.bulcan.2021.10.003 PMID: 34920804
pubmed: 34920804
pii: S0007-4551(21)00434-3
doi: 10.1016/j.bulcan.2021.10.003
pii:
doi:

Substances chimiques

Antibodies, Bispecific 0
Antigens, Neoplasm 0
FCRL5 protein, human 0
GPRC5D protein, human 0
Receptors, Fc 0
Receptors, G-Protein-Coupled 0
SLAMF7 protein, human 0
Signaling Lymphocytic Activation Molecule Family 0
ADP-ribosyl Cyclase 1 EC 3.2.2.6

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

S205-S212

Informations de copyright

Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Guillaume Escure (G)

CHU Lille, hôpital Huriez, service d'hématologie, 59000 Lille, France; Université de Lille, Unité CANTHER, Inserm UMR-S1277 & CNRS UMR9020, 59000 Lille, France.

Salomon Manier (S)

CHU Lille, hôpital Huriez, service d'hématologie, 59000 Lille, France; Université de Lille, Unité CANTHER, Inserm UMR-S1277 & CNRS UMR9020, 59000 Lille, France. Electronic address: salomon.manier@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Antigènes CD38 › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteur Fc › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Famille des molécules de signalisation de l'activation des lymphocytes › [Bispecific antibodies in multiple myeloma].
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › [Bispecific antibodies in multiple myeloma].